Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • inderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Följda bolag
    • Teamet
Regulatoriskt pressmeddelande

SensoDetect AB: Sensodetect embarks on strategic business mission to China and the Middle East: showcasing next-generation AI diagnostics and future ABR+ERP (EEG) technology roadmap to large investors

SensoDetect
Läs börsmeddelandet

Sensodetect AB, a pioneer in neurodiagnostic technology, today announced that its leadership team is undertaking an international business mission to China and the Middle East. The trip will highlight not only the company's commitment to market expansion but also its next-generation hardware and AI-driven diagnostic platform, alongside a long-term roadmap integrating Auditory Brainstem Response (ABR) with Event-Related Potentials (ERP) via EEG.

Advancing Regulatory Pathways in China

A central focus of the trip will be advancing the company's ongoing regulatory approval process with the National Medical Products Administration (NMPA) in China. Meetings with regulators, clinical partners, and key stakeholders are expected to stimulate progress toward approval and align on the final steps required for market entry. Sensodetect views NMPA approval as a critical milestone for expanding access to its breakthrough neurodiagnostic tools in the world's second-largest healthcare market.

Joint Venture and Investment Discussions

In parallel, the company will engage in joint venture discussions with leading Chinese investment and healthcare groups. These talks aim to give a large capital infusion and establish a long-term strategic collaboration that supports not only commercialization in China but also future research, development, and manufacturing partnerships in the region.

Next-Generation Technology

During the mission, Sensodetect will showcase its next version of its hardware in combination with its newly developed AI solution. This integrated approach is designed to enhance diagnostic accuracy, speed, and clinical usability.

Looking ahead, Sensodetect is also laying the foundation for it's next generation solution that combines ABR with ERP (EEG). This innovation represents a major step toward a more comprehensive neurodiagnostic platform, providing clinicians with deeper, objective insights into brain function.

Market Expansion in the Middle East

Following China, the Sensodetect team will visit the Middle East for business discussions with healthcare providers, distributors, and policymakers. The region presents strong demand for innovative diagnostic solutions, and the company sees significant opportunities to contribute to improved mental healthcare outcomes.

New Product Launch Timelines

The international mission will also serve as a platform for advancing discussions around product launch timelines. Sensodetect plans to align with regional partners on distribution strategies, market readiness, and clinical adoption to ensure a successful roll-out in both China and the Middle East.

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.